These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 29643471)

  • 1. Current state of immunotherapy for glioblastoma.
    Lim M; Xia Y; Bettegowda C; Weller M
    Nat Rev Clin Oncol; 2018 Jul; 15(7):422-442. PubMed ID: 29643471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
    Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
    Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
    Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
    Pollack IF; Okada H; Chambers WH
    Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
    Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current State of Immune-Based Therapies for Glioblastoma.
    Lim M; Weller M; Chiocca EA
    Am Soc Clin Oncol Educ Book; 2016; 35():e132-9. PubMed ID: 27249715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy and radiation in glioblastoma.
    Sahebjam S; Sharabi A; Lim M; Kesarwani P; Chinnaiyan P
    J Neurooncol; 2017 Sep; 134(3):531-539. PubMed ID: 28567588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.
    Habashy KJ; Mansour R; Moussalem C; Sawaya R; Massaad MJ
    Br J Cancer; 2022 Oct; 127(6):976-987. PubMed ID: 35662275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
    Antonopoulos M; VAN Gool SW; Dionysiou D; Graf N; Stamatakos G
    Anticancer Res; 2019 Apr; 39(4):2043-2051. PubMed ID: 30952748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.
    Aquino D; Gioppo A; Finocchiaro G; Bruzzone MG; Cuccarini V
    J Immunol Res; 2017; 2017():5813951. PubMed ID: 28512646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Baldini C; Romano PM; Varga A; Champiat S; Dumont S; Dhermain F; Louvel G; Marabelle A; Postel-Vinay S; Angevin E; Gazzah A; Ribrag V; Bahleda R; Michot JM; Hollebecque A; Soria JC; Massard C
    Bull Cancer; 2018 Dec; 105 Suppl 1():S59-S67. PubMed ID: 30595200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Immune Cell Therapy for Glioblastoma.
    Kang X; Zheng Y; Hong W; Chen X; Li H; Huang B; Huang Z; Tang H; Geng W
    Front Immunol; 2020; 11():544563. PubMed ID: 33193310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.